Schizophrenia & Psychoses
Type 2 diabetes is greater with second-generation antipsychotics than with non-second-generation antipsychotic psychotropic medications for patients aged 6 to 25 years.
The FDA issued a refusal to file letter for a new drug application.
Different clinical and neurobiologic pathways may be involved in treatment-resistant schizophrenia as it is not a homogeneous subgroup within the schizophrenia spectrum.
Researchers from the University of Texas Southwestern Medical Center have discovered the cellular receptor that causes weight gain from antipsychotic drugs.
Shared decision making encourages a clinical partnership that can result in optimal treatment outcomes.
Interventions targeted at improving medication adherence might mitigate adverse effects of cannabis use on psychosis outcomes.
Long-acting injectables should be considered earlier in the treatment of schizophrenia.
Increases in autonomic function may predict the occurrence and severity of auditory hallucinations in patients with schizophrenia, suggesting a regulation of these experiences by the autonomic nervous system.
Diabetes mellitus (DM) appears to be more prevalent in the psychiatric setting than in the general population.
The risk for rehospitalization was 22% lower during treatment with long-acting injectable antipsychotic medications compared with treatment with equivalent oral formulations in the total cohort.
Schizophrenia patients may benefit from a a specific type of talk therapy, according to a new study from the University of Pennsylvania.
Concomitant SSRI/SNRI use was associated with an increased diabetes risk in AAP-treated young people.
There is currently no approved drug combination for treatment-resistant schizophrenia.
In patients with schizophrenia being treated with clozapine or olanzapine, liraglutide significantly improved glucose tolerance, body weight, and other cardiometabolic disturbances.
Electroconvulsive therapy can be a clinically effective treatment for patients with severe forms of schizophrenia.
Long-term valbenazine may be beneficial in managing tardive dyskinesia.
Body mass index in patients with schizophrenia is linked to C-reactive protein.
Lurasidone is an atypical antipsychotic that has demonstrated efficacy in the treatment of schizophrenia in adolescents.
Mental disorders and psychotropic medication use are associated with an increased risk for fracture but are not fully captured by FRAX tool.
Schizophrenia was perceived as more distressful and with higher perceived social stigma than other disorders.
Scientists researched the association between multiple drug treatments for psychotic disorders and anticholinergic burden.
Cannabis is the most widely misused illicit drug.
Schizophrenia was associated with 13 to 15 years of potential life lost.
The risk for offspring's development of psychosis is connected to maternal weight gain during pregnancy.
A trial at 3 mental health centers in The Netherlands revealed that patients with financial incentives have better compliance.
Adding high-dose B vitamins to traditional antipsychotic treatments reduces schizophrenia symptoms more than traditional treatments alone.
The FDA has approved a new treatment for adolescents between the ages of 13 and 17 years who are diagnosed with schizophrenia.
Researchers profiled which young people may do well after first-episode psychosis without medication.
These study results indicate that early intervention with low doses of metformin in patients with few metabolic abnormalities may be beneficial.
Targeting negative symptoms in patients with schizophrenia may be more effective in improving patients' QoL.
Psychiatry Advisor Articles
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Duration of Untreated Depression Predicts Depression Severity
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Bipolar Depression Benefits From Midday Bright Light Therapy
- Buprenorphine, Methadone Combined With CNS Depressants May Lead to SAEs